Catalog No.S1675 Synonyms: RU 0211

For research use only.

Lubiprostone (RU 0211) is an activator of ClC-2 chloride channels, used in the management of idiopathic chronic constipation.

Lubiprostone  Chemical Structure

CAS No. 136790-76-6

Purity & Quality Control

Choose Selective Chloride Channel Inhibitors

Biological Activity

Description Lubiprostone (RU 0211) is an activator of ClC-2 chloride channels, used in the management of idiopathic chronic constipation.
ClC-2 chloride channels [1]
In vitro

Lubiprostone induces a robust secretory response in T84 monolayers. Lubiprostone induces a rise in cAMP levels that was sensitive to EP(4)-receptor blockage in T84 cells. [1] Lubiprostone induces a contraction in rat and human stomach longitudinal muscle, which is inhibited by pretreatment with the EP(1) receptor antagonist but not by the EP(3) or EP(4) receptor antagonists. Lubiprostone also reduces electrically stimulated, neuronal contractions in rat and human colon circular muscle preparations. [2] Lubiprostone (1 mM) stimulates higher elevations in TER despite lower I(sc) responses compared with the nonselective secretory agonist PGE(2) (1 mM). Lubiprostone significantly reduces mucosal-to-serosal fluxes of (3)H-labeled mannitol to levels comparable to those of normal control tissues and restored occludin localization to tight junctions. [3] Lubiprostone causes comparable and maximal increases of I(sc) in T84 cells. Lubiprostone-induced increases in iodide efflux are ~80% of those obtained with forskolin. Lubiprostone activates Cl(-) secretion in T84 cells via cAMP, protein kinase A, and by increasing apical membrane CFTR protein. [4] Lubiprostone, applied to the small intestinal mucosa in eight concentrations ranging from 1-3000 nM, evokes increases in Isc in a concentration-dependent manner with an EC50 of 42.5 nM. Lubiprostone applied to the mucosa of the colon in eight concentrations ranging from 1-3000 nM evokes increases in Isc in a concentration-dependent manner with an EC50 of 31.7 nM. [5]

In vivo Lubiprostone induces a CdCl(2)-insensitive secretory response in mouse intestine, but fail to induce intestinal Cl(-) secretion in Cftr-null mice. [1]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 78 mg/mL
(199.76 mM)
Ethanol 78 mg/mL
(199.76 mM)
Water Insoluble

Chemical Information

Molecular Weight 390.46


CAS No. 136790-76-6
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01469819 Completed Drug: Lubiprostone Chronic Idiopathic Constipation Texas Tech University Health Sciences Center El Paso|Takeda Pharmaceuticals North America Inc. June 2012 Phase 2|Phase 3
NCT01324284 Completed Drug: Lubiprostone Colorectal Carcinoma Asian Institute of Gastroenterology India March 2011 Phase 3
NCT00934479 Completed Drug: Lubiprostone Other Constipation|Irritable Bowel Syndrome Mayo Clinic|Arizona State University|Takeda Pharmaceuticals North America Inc. April 2010 Phase 1
NCT01085643 Completed Drug: Lubiprostone|Drug: Placebo Constipation-predominant Irritable Bowel Syndrome Cedars-Sinai Medical Center|Takeda Pharmaceuticals North America Inc. March 2010 Not Applicable
NCT00985569 Withdrawn -- Constipation Synergy Health Solutions November 2009 --

(data from, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Lubiprostone | Lubiprostone ic50 | Lubiprostone price | Lubiprostone cost | Lubiprostone solubility dmso | Lubiprostone purchase | Lubiprostone manufacturer | Lubiprostone research buy | Lubiprostone order | Lubiprostone mouse | Lubiprostone chemical structure | Lubiprostone mw | Lubiprostone molecular weight | Lubiprostone datasheet | Lubiprostone supplier | Lubiprostone in vitro | Lubiprostone cell line | Lubiprostone concentration | Lubiprostone nmr